[HTML][HTML] A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active …

RM Fleischmann, R Alten, M Pileckyte… - Arthritis Research & …, 2018 - Springer
Background This double-blind, randomized, 78-week study evaluated the efficacy, safety,
immunogenicity, pharmacokinetics, and pharmacodynamics of PF-06410293, a candidate …

Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks …

RM Fleischmann, DF Alvarez, AE Bock… - RMD open, 2021 - rmdopen.bmj.com
Objective To investigate the efficacy, safety, immunogenicity and pharmacokinetics of
biosimilar adalimumab (ADL) PF-06410293 (ADL-PF; adalimumab-afzb) versus EU-sourced …

[HTML][HTML] Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference …

RM Fleischmann, DF Alvarez, AE Bock… - Arthritis research & …, 2021 - Springer
Abstract Background/objective REFLECTIONS B538–02 is a randomized, double-blind
comparative study of the adalimumab (ADL) biosimilar PF-06410293,(ADL-PF), and …

[HTML][HTML] Usability study of PF-06410293, an adalimumab biosimilar, by prefilled pen: open-label, single-arm, sub-study of a phase 3 trial in patients with rheumatoid …

RM Fleischmann, AE Bock, W Zhang… - Rheumatology and …, 2022 - Springer
Introduction The aim of this sub-study was to evaluate injection success of patients with
rheumatoid arthritis (RA) and their caregivers administering the adalimumab (ADL) …

Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous …

DS Cox, DF Alvarez, AE Bock… - … Pharmacology in Drug …, 2021 - Wiley Online Library
This open‐label, single‐dose, randomized, parallel‐group, 2‐arm phase 1 bioequivalence
(BE) study assessed the pharmacokinetics (PK), safety, and tolerability of PF‐06410293 …

Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis

J Kay, AE Bock, M Rehman, W Zhang, M Zhang… - RMD open, 2022 - rmdopen.bmj.com
Objectives This exploratory analysis investigated the potential use of the multibiomarker
disease activity (MBDA) score to support biosimilarity assessments using data from two …

THU0182 A comparative clinical study of pf-06410293, a candidate adalimumab biosimilar, and reference adalimumab for the treatment of active rheumatoid arthritis

R Alten, RM Fleischmann, M Pileckyte, SY Hua… - 2018 - ard.bmj.com
Background To confirm the efficacy, safety and immunogenicity of biosimilars, a comparative
clinical study is typically required. Objectives This double-blind, randomised, 78 week (wk) …